Work

Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-148668

Authors: Abdulraheem Yacoub, Uma Borate, Raajit Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver

Institutions: The University of Kansas Cancer Center, Oregon Health & Science University, Memorial Sloan Kettering Cancer Center, City Of Hope National Medical Center, Roswell Park Comprehensive Cancer Center, Cleveland Clinic, Massachusetts General Hospital, Icahn School of Medicine at Mount Sinai, Emory University, University of Southern California, Montefiore Medical Center, Washington University in St. Louis, University of California, Los Angeles, Incyte (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3213293168

Cites:

Cited by: 2

Related to: 10